Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuv… (NCT06597227) | Clinical Trial Compass
RecruitingNot Applicable
Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
China404 participantsStarted 2024-03-01
Plain-language summary
We plan to evaluate the efficacy and safety of proximal gastric vs. total gastric radical resection after SOX combined with anti-PD-1 neoadjuvant therapy in locally advanced upper gastric cancer
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;
✓. Age 18-75 years old (at the time of signing the informed consent), both male and female;
✓. Histologically and/or cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT/MRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;
✓. Have not received systematic treatment for the current disease, including anti-tumor chemoradiotherapy/immunotherapy;
✓. ECOG score 0-1;
✓. Expected survival ≥6 months;
✓. Preoperative chest, abdominal, pelvic CT or PET-CT to exclude distant metastasis;
✓. The major organs function well and meet the following criteria:
Exclusion criteria
✕. The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;
✕. Age 18-75 years old (at the time of signing the informed consent), both male and female;
✕. Histologically and/or cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT/MRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;